References
Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol 2021;19:110–21.
Ike AC, Onu CJ, Ononugbo CM, Reward EE, Muo SO. Immune response to herpes simplex virus infection and vaccine development. Vaccines 2020;8:1–22.
Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 2011;9:369–81.
Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion and entry: a story with many characters. Viruses 2012;4:800–32.
Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006;313:217–20.
Bu GL, Xie C, Kang YF, Zeng MS, Sun C. How EBV infects: the tropism and underlying molecular mechanism for viral infection. Viruses 2022;14:2372.
Sun C, Kang YF, Fang XY, Liu YN, Bu GL, Wang AJ, et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 2023;31:1882–1897.e10.
Bender FC, Samanta M, Heldwein EE, Leon MP, Bilman E, Lou H, et al. Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol 2007;81:3827–41.
Zhong L, Zhang W, Krummenacher C, Chen Y, Zheng Q, Zhao Q, et al. Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents. Trends Microbiol 2023;31:788–804.
Baquero E, Albertini AAV, Gaudin Y. Recent mechanistic and structural insights on class Ⅲ viral fusion glycoproteins. Curr Opin Struct Biol 2015;33:52–60.
Vollmer B, Prazák V, Vasishtan D, Jeffery EE, Hernandez A, Vallbracht M, et al. The prefusion structure of herpes simplex virus glycoprotein B. Sci Adv 2020;6:1–12.
Liu Y, Heim KP, Che Y, Chi X, Qiu X, Han S, et al. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci Adv 2021;7:1–10.
Theobald SJ, Kreer C, Khailaie S, Bonifacius A, Eiz B, Figueiredo C, et al. Repertoire characterization and validation of GB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. PLoS Pathog 2020;16:e1008560.
Zhang X, Hong JP, Zhong L, Wu Q, Zhang S, Zhu Q, et al. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proc Natl Acad Sci USA 2022;119:1–12.
Snijder J, Ortego MS, Weidle C, Stuart A, Gray M, McElrath J, et al. An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on epstein-barr virus. Immunity 2018;48:799–811.e9.
Sun C, Kang YF, Liu YT, Kong XW, Xu HQ, Xiong D, et al. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Signal Transduct Targeted Ther 2022;7:42.
Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 2017;14:290–6.
Jumper J, Evans R, Pritzel A, Green T, Figuronov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583–9.
Pettersen EF, Goddard TD, Huang CC, Meng E, Couch G, Croll T, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci 2021;30:70–82.
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan P, McWilliam H, et al. Clustal W and clustal X version 2.0. Bioinformatics 2007;23:2947–8.
Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 2014;42:320–4.
